Search results for "TAXA"

showing 10 items of 268 documents

Crossing kingdoms:How can art open up new ways of thinking about science?

2020

“Crossing Kingdoms” is an artist-led experiment in the biological fusion of mammalian and yeast cells and the cultural discussions of these phenomena. We present this collaboration as an experiment in responsible research and innovation (RRI), an institutionalized format for ensuring that researchers reflect on the wider social dimensions of their work. Our methods challenged us as researchers to reflect on interdisciplinary collaboration and the possibility of innovating in biology for artistic purposes, challenged audiences to reflect on biological boundaries, and challenged both groups to reflect on what it means to be responsible in science. We conclude that our experiment in RRI was su…

0301 basic medicineHistologylcsh:BiotechnologyBiomedical Engineeringresponsible research and innovationhybrid taxaBioengineering02 engineering and technologySocial dimension03 medical and health sciencesSynthetic biologyKingdominterdisciplinaritylcsh:TP248.13-248.65responsible research and innovation (RRI)Responsible Research and InnovationBioengineering and Biotechnologyart-science collaboration021001 nanoscience & nanotechnology030104 developmental biologyPerspectiveStandard protocolEngineering ethicssynthetic biology0210 nano-technologyBiotechnology
researchProduct

Fungal Planet description sheets: 785– 867

2018

Novel species of fungi described in this study include those from various countries as follows: Angola, Gnomoniopsis angolensis and Pseudopithomyces angolensis on unknown host plants. Australia, Dothiora corymbiae on Corymbia citriodora, Neoeucasphaeria eucalypti (incl. Neoeucasphaeria gen. nov.)on Eucalyptus sp., Fumagopsis stellae on Eucalyptus sp., Fusculina eucalyptorum (incl. Fusculinaceae fam. nov.) on Eucalyptus socialis, Harknessia corymbiicola on Corymbia maculata, Neocelosporium eucalypti (incl. Neocelosporium gen. nov., Neocelosporiaceae fam. nov. and Neocelosporiales ord. nov.) on Eucalyptus cyanophylla, Neophaeomoniella corymbiae on Corymbia citriodora, Neophaeomoniella eucalyp…

0301 basic medicineITS nrDNA barcodesfood.ingredientEvolutionCorymbia citriodora:Matematikk og Naturvitenskap: 400::Zoologiske og botaniske fag: 480 [VDP]Cape verde03 medical and health sciencesfoodBehavior and SystematicsNew taxaSystematicsBotanyITS nrDNA barcodeEcology Evolution Behavior and SystematicsLSUbiologyEcologyEucalyptus brassianaSettore BIO/02 - Botanica Sistematica030108 mycology & parasitologybiology.organism_classificationEucalyptusEucalyptus pilularisEucalyptus camaldulensisEucalyptus gracilisCorymbia maculata
researchProduct

A [13]rotaxane assembled via a palladium molecular capsule

2019

Molecules that are the size of small proteins are difficult to make. The most frequently examined route is via self-assembly, and one particular approach involves molecular nanocapsules, where ligands are designed that will enforce the formation of specific polyhedra of metals within the core of the structure. Here we show that this approach can be combined with mechanically interlocking molecules to produce nanocapsules that are decorated on their exterior. This could be a general route to very large molecules, and is exemplified here by the synthesis and structural characterization of a [13]rotaxane, containing 150 metal centres. Small angle X-ray scattering combined with atomistic molecu…

0301 basic medicineMaterials scienceRotaxaneScienceInterlocked moleculesSupramolecular chemistryGeneral Physics and Astronomychemistry.chemical_elementNanotechnology02 engineering and technologyGeneral Biochemistry Genetics and Molecular BiologyNanocapsulesArticleMetal03 medical and health sciencesMolecular dynamicsMoleculelcsh:ScienceMultidisciplinaryMolecular capsulesQGeneral Chemistry021001 nanoscience & nanotechnologyCharacterization (materials science)030104 developmental biologychemistryvisual_artvisual_art.visual_art_mediumlcsh:Q0210 nano-technologyPalladiumNature Communications
researchProduct

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

2014

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

0301 basic medicineOncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerTrastuzumabInternal medicineHumansMedicineMaytansineProgression-free survivalNeoplasm Metastasisskin and connective tissue diseasesTaxanebusiness.industryCancerHematologyTrastuzumabmedicine.diseaseMetastatic breast cancerClinical trial030104 developmental biologyClinical Trials Phase III as TopicOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisDisease ProgressionFemaleNeoplasm Recurrence Localbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent

2018

Indicaxanthin is a bioactive and bioavailable betalain pigment extracted from Opuntia ficus indica fruits. Indicaxanthin has pharmacokinetic proprieties, rarely found in other phytochemicals, and it has been demonstrated that it provides a broad-spectrum of pharmaceutical activity, exerting anti-proliferative, anti-inflammatory, and neuromodulator effects. The discovery of the Indicaxanthin physiological targets plays an important role in understanding the biochemical mechanism. In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydr…

0301 basic medicineStatistics and ProbabilityMolecular dynamicPyridinesKainate receptorIndicaxanthinPhytochemical01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyDocking03 medical and health scienceschemistry.chemical_compoundNeoplasmsGlutamate carboxypeptidase IIData MiningHumansEnzyme InhibitorsMM-GBSAPharmacophore modelingBinding SitesGeneral Immunology and MicrobiologyReverse screening010405 organic chemistryAnti-cancerApplied MathematicsPhosphodiesteraseOpuntiaPhosphoserine phosphataseInositol trisphosphateGeneral MedicineAntineoplastic Agents Phytogenic0104 chemical sciencesBetaxanthinsNeoplasm ProteinsNeuromodulatorMolecular Docking SimulationAnti-inflammatory agent030104 developmental biologychemistryBiochemistryDocking (molecular)Modeling and SimulationPharmacophoreGeneral Agricultural and Biological SciencesIndicaxanthin
researchProduct

Inhabiting plant roots, nematodes, and truffles—polyphilus, a new helotialean genus with two globally distributed species

2018

Fungal root endophytes, including the common group of dark septate endophytes (DSEs), represent different taxonomic groups and potentially diverse life strategies. In this study, we investigated two unidentified helotialean lineages found previously in a study of DSE fungi of semiarid grasslands, from several other sites, and collected recently from a pezizalean truffle ascoma and eggs of the cereal cyst nematode Heterodera filipjevi. The taxonomic positions and phylogenetic relationships of 21 isolates with different hosts and geographic origins were studied in detail. Four loci, namely, nuc rDNA ITS1-5.8S-ITS2 (internal transcribed spacer [ITS]), partial 28S nuc rDNA (28S), partial 18S nu…

0301 basic medicineSystematicZygotePhysiologyLeotiomycetesHyaloscyphaceaeDNA RibosomalPlant Roots03 medical and health sciencesAscomycotaPhylogeneticsDNA Ribosomal SpacerRNA Ribosomal 28SBotanyRNA Ribosomal 18SGeneticsAnimalsCluster AnalysisTylenchoideaInternal transcribed spacerDNA FungalMolecular BiologyRibosomal DNAPhylogenyEcology Evolution Behavior and SystematicsComputingMilieux_MISCELLANEOUSTaxonomy[SDV.EE]Life Sciences [q-bio]/Ecology environmentHeterodera filipjeviCereal cyst nematodebiologyPhylogenetic tree3 new taxaSequence Analysis DNACell BiologyGeneral Medicine15. Life on land030108 mycology & parasitologybiology.organism_classificationEndophyteRNA Ribosomal 5.8S030104 developmental biologyHelotialesRNA Polymerase IIHyaloscyphaceaeMycologia
researchProduct

An overview on anti-tubulin agents for the treatment of lymphoma patients

2020

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the …

0301 basic medicineVinca alkaloidsLymphomaMitosisAntineoplastic AgentsApoptosismacromolecular substancesMicrotubulesAntibody drug conjugatesTaxanes03 medical and health sciences0302 clinical medicineTubulinMicrotubulemedicineAnimalsHumansMaytansinePharmacology (medical)MetaphaseMitosisAnaphasePharmacologybiologybusiness.industryCancerCombination chemotherapymedicine.diseaseTubulin ModulatorsLymphoma030104 developmental biologyTubulinEpothilones030220 oncology & carcinogenesisbiology.proteinCancer researchDolastatinsbusinessPharmacology & Therapeutics
researchProduct

The impact of fermentation processes on the production, retention and bioavailability of carotenoids: An overview

2020

Abstract Background Carotenoids are isoprenoids compounds widely distributed in foods. A difference of carotenoids relative to other food bioactives is that some can be converted into compounds exhibiting vitamin A activity, which is essential for humans. Besides, they are more versatile as they are also natural pigments, antioxidants and can be involved in health-promoting actions. Lately, they are also attracting interest in relation to skin beauty. Their importance for different industry sector (foods, feeds, pharmaceutical, cosmetics) is therefore indisputable. Carotenoids can be obtained by different approaches including extraction from appropriate sources or synthesis. Scope and appro…

0301 basic medicineVitaminchemistry.chemical_classification030109 nutrition & dieteticsorganic chemicalsmedia_common.quotation_subjectfood and beveragesCosmeticsLycopeneBioavailability03 medical and health scienceschemistry.chemical_compound030104 developmental biologychemistryAstaxanthinFermentationFood scienceFermentation in food processingCarotenoidFood ScienceBiotechnologymedia_commonTrends in Food Science & Technology
researchProduct